Introduction on Cardiac Resynchronisation Therapy and Heart Failure: Perspective from 5P Medicine
The prevalence of heart failure (HF) is still high1 and is rising in developing countries.2 Despite optimal medical therapy, refractory HF is a common occurrence and remains a “global disease requiring global response.”3 The emergence of cardiac resynchronisation therapy (CRT), has brought a new paradigm in the management of HF. CRT has been the most promising device therapy in mild-to-severe HF over the past two decades,4 has improved the prognosis of HF and has been incorporated into therapeutic guidelines.5,6 The 20-year history of CRT illustrates the concept of “from bench to bedside” and this article aims to review the use of CRT in the context of 5P medicine-prevention, personalisation, prediction and participation as well as promotion.